Evidence map›Paper›PMID 33440698›Full record

ArticleVaccines2021

Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern.

Vilmos Palya, Tímea Tatár-Kis, Abdel Satar A Arafa, Balázs Felföldi, Tamás Mató, Ahmed Setta

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vilmos PalyaScientific Support and Investigation Unit, Ceva-Phylaxia Co. Ltd., Ceva Animal Health, 5 Szallas Utca, 1107 Budapest, Hungary.ORCID 0000-0003-3319-9995
Tímea Tatár-KisScientific Support and Investigation Unit, Ceva-Phylaxia Co. Ltd., Ceva Animal Health, 5 Szallas Utca, 1107 Budapest, Hungary.ORCID 0000-0001-7906-7758
Abdel Satar A ArafaCentral Laboratory for Quality Control of Poultry Production, Animal Health Research Institute, Agriculture Research Center, 7 Nadi El-Seid Street, Dokki, Giza 12618, Egypt.
Balázs FelföldiScientific Support and Investigation Unit, Ceva-Phylaxia Co. Ltd., Ceva Animal Health, 5 Szallas Utca, 1107 Budapest, Hungary.
Tamás MatóScientific Support and Investigation Unit, Ceva-Phylaxia Co. Ltd., Ceva Animal Health, 5 Szallas Utca, 1107 Budapest, Hungary.
Ahmed SettaCeva Animal Health, 5 Street 277, Maadi, Cairo 11435, Egypt.ORCID 0000-0002-9088-6233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The control of Newcastle disease (ND) highly relies on vaccination. Immunity provided by a ND vaccine can be characterized by measuring the level of clinical protection and reduction in challenge virus shedding. The extent of shedding depends a lot on the characteristics of vaccine used and the quality of vaccination, but influenced also by the genotype of the challenge virus. We demonstrated that vaccination of SPF chicks with recombinant herpesvirus of turkey expressing the F-gene of genotype I ND virus (rHVT-ND) provided complete clinical protection against heterologous genotype VII.1.1 ND virus strain and reduced challenge virus shedding significantly. 100% of clinical protection was achieved already by 3 weeks of age, irrespective of the challenge route (intra-muscular or intra-nasal) and vaccination blocked cloacal shedding almost completely. Interestingly, oro-nasal shedding was different in the two challenge routes: less efficiently controlled following intra-nasal than intra-muscular challenge. Differences in the shedding pattern between the two challenge routes indicate that rHVT-ND vaccine induces strong systemic immunity, that is capable to control challenge virus dissemination in the body (no cloacal shedding), even when it is a heterologous strain, but less efficiently, although highly significantly (

Indexed as

challenge routegenotype VIINewcastle disease virusrecombinant turkey herpesvirussheddingvaccine

Identifiers

PMID33440698
PMCPMC7826937
OpenAlexW3119167420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.